Alvogen has launched the first generic equivalent of multiple sclerosis treatment Copaxone in Europe, with the product said to "provide an affordable high quality alternative to MS patients".
Remurel (glatiramer acetate) will be marketed as a once daily subcutaneous 20mg prefilled syringe, with a proprietary auto-injector device called Autoxon.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Sep 16